Global Human Microbiome Therapeutics Market 2018-2022

ヒトマイクロバイオーム治療薬の世界市場2018-2022:胃腸障害、免疫学的症状、その他

◆タイトル:Global Human Microbiome Therapeutics Market 2018-2022
◆商品コード:IRTNTR20038
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年12月27日
◆ページ数:106
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社が発行した当調査レポートでは、ヒトマイクロバイオーム治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、ヒトマイクロバイオーム治療薬の世界市場規模及び予測、主要国別分析、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。Technavio社はヒトマイクロバイオーム治療薬の世界市場が2018-2022年期間中に年平均14.19%成長すると予測しています。当レポート上に記載されている主な企業は、ENTEROME Bioscience、Rebiotix、Seres Therapeutics、Vedanta Biosciences等です。

About Human Microbiome Therapeutics Microbiome Therapeutics is developing evidence-based microbiome modulators designed to shift bacterial populations and their environment in the gastrointestinal (GI) tract to better manage serious health conditions. GIT is an organ system that includes the mouth, esophagus, stomach, and the intestines. The GIT can be divided into upper Git and lower GIT. Upper GIT consists of the oral cavity, the pharynx, the esophagus, the stomach, and the duodenum. The lower GIT consists of the small and large intestines. Gastrointestinal disorders refer to diseases involving the GIT. Microbiome therapeutics are being increasingly adopted for the treatment of gastrointestinal disorders such as IBS and ulcerative colitis.

Technavio’s analysts forecast the global human microbiome therapeutics market to grow at a CAGR of 14.19% during the period 2018-2022.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global human microbiome therapeutics market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of human microbiome therapeutics.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Human Microbiome Therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• ENTEROME Bioscience
• Rebiotix
• Seres Therapeutics
• Vedanta Biosciences

[Other prominent vendors]
• Bristol-Myers Squibb
• Johnson & Johnson
• Takeda Pharmaceutical

[Market driver]
• Side effects of the existing treatments
• For a full, detailed list, view our report

[Market trend]
• Growing investments from venture capitalists
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
• Market outline

PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market segmentation analysis

PART 06: MARKET SIZING
• Market definition
• Market size and forecast

PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: PIPELINE LANDSCAPE

PART 09: MARKET SEGMENTATION BY THERAPEUTIC APPLICATION
• Comparison by therapeutic application
• Gastrointestinal disorders
• Immunological conditions
• Others
• Market opportunity by therapeutic application

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
• Comparison by region
• Human microbiome therapeutics market in Americas
• Human microbiome therapeutics market in EMEA
• Human microbiome therapeutics market in APAC
• Key leading countries
• Market opportunity by region

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 14: MARKET TRENDS
• Increase in industry-academia collaboration
• Increasing investments by venture capitalists

PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive analysis

PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ENTEROME Bioscience
• Rebiotix
• Seres Therapeutics
• Vedanta Biosciences

PART 17: APPENDIX
• List of abbreviations

[List of Exhibits]
Exhibit 01: Microbiome by host
Exhibit 02: Common prebiotics
Exhibit 03: Major sources of prebiotics
Exhibit 04: Benefits of probiotics
Exhibit 05: Parent market
Exhibit 06: Global human microbiome therapeutics market: Characteristics
Exhibit 07: Global human microbiome therapeutics market: Segmentation
Exhibit 08: Market definition: Inclusions and exclusions checklist
Exhibit 09: Market size 2017
Exhibit 10: Validation techniques employed for market sizing 2017
Exhibit 11: Global human microbiome therapeutics market 2017-2022 ($ millions)
Exhibit 12: Global human microbiome therapeutics market: Year-over-year growth
Exhibit 13: Five forces analysis 2017
Exhibit 14: Five forces analysis 2022
Exhibit 15: Bargaining power of buyers
Exhibit 16: Bargaining power of suppliers
Exhibit 17: Threat of new entrants
Exhibit 18: Threat of substitutes
Exhibit 19: Threat of rivalry
Exhibit 20: Market condition: Five forces 2017
Exhibit 21: Pipeline landscape
Exhibit 22: Key clinical trials
Exhibit 23: Global human microbiome therapeutics market by therapeutic application 2017-2022 (% share)
Exhibit 24: Comparison by therapeutic application
Exhibit 25: Global human microbiome therapeutics market by gastrointestinal disorders 2017-2022 ($ millions)
Exhibit 26: Global human microbiome therapeutics market by gastrointestinal disorders: Year-over-year growth 2018-2022
Exhibit 27: Global human microbiome therapeutics market by immunological conditions 2017-2022 ($ millions)
Exhibit 28: Global human microbiome therapeutics market by immunological conditions: Year-over-year growth 2018-2022
Exhibit 29: Global human microbiome therapeutics market by others 2017-2022 ($ millions)
Exhibit 30: Global human microbiome therapeutics market by others: Year-over-year growth 2018-2022
Exhibit 31: Market opportunity by therapeutic application
Exhibit 32: Customer landscape
Exhibit 33: Global human microbiome therapeutics market by region 2017-2022 (% share)
Exhibit 34: Regional comparison
Exhibit 35: Human microbiome therapeutics market in Americas 2017-2022 ($ millions)
Exhibit 36: Human microbiome therapeutics market in Americas: Year-over-year growth
Exhibit 37: Human microbiome therapeutics market in EMEA 2017-2022 ($ millions)
Exhibit 38: Human microbiome therapeutics market in EMEA: Year-over-year growth 2018-2022
Exhibit 39: Human microbiome therapeutics market in APAC 2017-2022 ($ millions)
Exhibit 40: Human microbiome therapeutics market in APAC: Year-over-year growth 2018-2022
Exhibit 41: Top Asian countries in terms of population with diabetes (millions)
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity by region
Exhibit 44: Global obesity facts 2014
Exhibit 45: Factors causing changes in human microbiome
Exhibit 46: Antibiotic resistance steps
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Competitive structure analysis of global microbiome therapeutics market
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: ENTEROME Bioscience: Overview
Exhibit 54: ENTEROME Bioscience: Business segments
Exhibit 55: ENTEROME Bioscience: Organizational developments
Exhibit 56: ENTEROME Bioscience: Geographic focus
Exhibit 57: ENTEROME Bioscience: Segment focus
Exhibit 58: ENTEROME Bioscience: Key offerings
Exhibit 59: Rebiotix: Overview
Exhibit 60: Rebiotix: Business segments
Exhibit 61: Rebiotix: Organizational developments
Exhibit 62: Rebiotix: Geographic focus
Exhibit 63: Rebiotix: Segment focus
Exhibit 64: Rebiotix: Key offerings
Exhibit 65: Seres Therapeutics: Overview
Exhibit 66: Seres Therapeutics: Business segments
Exhibit 67: Seres Therapeutics: Organizational developments
Exhibit 68: Seres Therapeutics: Geographic focus
Exhibit 69: Seres Therapeutics: Segment focus
Exhibit 70: Seres Therapeutics: Key offerings
Exhibit 71: Vedanta Biosciences: Overview
Exhibit 72: Vedanta Biosciences: Business segments
Exhibit 73: Vedanta Biosciences: Organizational developments
Exhibit 74: Vedanta Biosciences: Geographic focus
Exhibit 75: Vedanta Biosciences: Segment focus
Exhibit 76: Vedanta Biosciences: Key offerings



【掲載企業】

ENTEROME Bioscience, Rebiotix, Seres Therapeutics, Vedanta Biosciences, Bristol-Myers Squibb, Johnson & Johnson, and Takeda Pharmaceutical.


★調査レポート[ヒトマイクロバイオーム治療薬の世界市場2018-2022:胃腸障害、免疫学的症状、その他] (Global Human Microbiome Therapeutics Market 2018-2022 / IRTNTR20038)販売に関する免責事項
[ヒトマイクロバイオーム治療薬の世界市場2018-2022:胃腸障害、免疫学的症状、その他] (Global Human Microbiome Therapeutics Market 2018-2022 / IRTNTR20038)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆